CELC
Price
$52.42
Change
+$2.04 (+4.05%)
Updated
Aug 22 closing price
Capitalization
2.22B
85 days until earnings call
MRSN
Price
$7.75
Change
-$0.36 (-4.44%)
Updated
Aug 22 closing price
Capitalization
38.68M
79 days until earnings call
Interact to see
Advertisement

CELC vs MRSN

Header iconCELC vs MRSN Comparison
Open Charts CELC vs MRSNBanner chart's image
Celcuity
Price$52.42
Change+$2.04 (+4.05%)
Volume$956.46K
Capitalization2.22B
Mersana Therapeutics
Price$7.75
Change-$0.36 (-4.44%)
Volume$71.86K
Capitalization38.68M
CELC vs MRSN Comparison Chart in %
Loading...
CELC
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
MRSN
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
CELC vs. MRSN commentary
Aug 24, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CELC is a Buy and MRSN is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Aug 24, 2025
Stock price -- (CELC: $52.42 vs. MRSN: $7.75)
Brand notoriety: CELC and MRSN are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: CELC: 66% vs. MRSN: 30%
Market capitalization -- CELC: $2.22B vs. MRSN: $38.68M
CELC [@Biotechnology] is valued at $2.22B. MRSN’s [@Biotechnology] market capitalization is $38.68M. The market cap for tickers in the [@Biotechnology] industry ranges from $101.31B to $0. The average market capitalization across the [@Biotechnology] industry is $1.86B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

CELC’s FA Score shows that 1 FA rating(s) are green whileMRSN’s FA Score has 0 green FA rating(s).

  • CELC’s FA Score: 1 green, 4 red.
  • MRSN’s FA Score: 0 green, 5 red.
According to our system of comparison, CELC is a better buy in the long-term than MRSN.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

CELC’s TA Score shows that 4 TA indicator(s) are bullish while MRSN’s TA Score has 5 bullish TA indicator(s).

  • CELC’s TA Score: 4 bullish, 5 bearish.
  • MRSN’s TA Score: 5 bullish, 4 bearish.
According to our system of comparison, MRSN is a better buy in the short-term than CELC.

Price Growth

CELC (@Biotechnology) experienced а +1.22% price change this week, while MRSN (@Biotechnology) price change was +8.24% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +2.57%. For the same industry, the average monthly price growth was +18.06%, and the average quarterly price growth was +26.94%.

Reported Earning Dates

CELC is expected to report earnings on Nov 17, 2025.

MRSN is expected to report earnings on Nov 11, 2025.

Industries' Descriptions

@Biotechnology (+2.57% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
CELC($2.22B) has a higher market cap than MRSN($38.7M). CELC YTD gains are higher at: 300.458 vs. MRSN (-78.322). MRSN has higher annual earnings (EBITDA): -68.88M vs. CELC (-135.56M). CELC has more cash in the bank: 168M vs. MRSN (77M). MRSN has less debt than CELC: MRSN (20.6M) vs CELC (99.4M). MRSN has higher revenues than CELC: MRSN (34.8M) vs CELC (0).
CELCMRSNCELC / MRSN
Capitalization2.22B38.7M5,747%
EBITDA-135.56M-68.88M197%
Gain YTD300.458-78.322-384%
P/E RatioN/AN/A-
Revenue034.8M-
Total Cash168M77M218%
Total Debt99.4M20.6M483%
FUNDAMENTALS RATINGS
CELC vs MRSN: Fundamental Ratings
CELC
MRSN
OUTLOOK RATING
1..100
9671
VALUATION
overvalued / fair valued / undervalued
1..100
86
Overvalued
87
Overvalued
PROFIT vs RISK RATING
1..100
24100
SMR RATING
1..100
99100
PRICE GROWTH RATING
1..100
3488
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
9050

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

CELC's Valuation (86) in the Miscellaneous Commercial Services industry is in the same range as MRSN (87) in the Biotechnology industry. This means that CELC’s stock grew similarly to MRSN’s over the last 12 months.

CELC's Profit vs Risk Rating (24) in the Miscellaneous Commercial Services industry is significantly better than the same rating for MRSN (100) in the Biotechnology industry. This means that CELC’s stock grew significantly faster than MRSN’s over the last 12 months.

CELC's SMR Rating (99) in the Miscellaneous Commercial Services industry is in the same range as MRSN (100) in the Biotechnology industry. This means that CELC’s stock grew similarly to MRSN’s over the last 12 months.

CELC's Price Growth Rating (34) in the Miscellaneous Commercial Services industry is somewhat better than the same rating for MRSN (88) in the Biotechnology industry. This means that CELC’s stock grew somewhat faster than MRSN’s over the last 12 months.

CELC's P/E Growth Rating (100) in the Miscellaneous Commercial Services industry is in the same range as MRSN (100) in the Biotechnology industry. This means that CELC’s stock grew similarly to MRSN’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
CELCMRSN
RSI
ODDS (%)
Bearish Trend 2 days ago
89%
Bullish Trend 2 days ago
89%
Stochastic
ODDS (%)
Bearish Trend 2 days ago
89%
Bearish Trend 2 days ago
90%
Momentum
ODDS (%)
Bullish Trend 3 days ago
87%
Bullish Trend 2 days ago
82%
MACD
ODDS (%)
Bearish Trend 2 days ago
90%
Bullish Trend 2 days ago
84%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
84%
Bullish Trend 2 days ago
81%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
81%
Bearish Trend 2 days ago
90%
Advances
ODDS (%)
Bullish Trend 2 days ago
83%
Bullish Trend 3 days ago
83%
Declines
ODDS (%)
Bearish Trend 4 days ago
86%
Bearish Trend 13 days ago
89%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
90%
Aroon
ODDS (%)
Bullish Trend 2 days ago
83%
N/A
View a ticker or compare two or three
Interact to see
Advertisement
CELC
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
MRSN
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
ABSZX21.310.63
+3.05%
AB Discovery Value Z
OAYIX31.550.58
+1.87%
Oakmark International Advisor
FCIHX17.460.27
+1.57%
NYLI PineStone International Equity Cl P
TQMVX18.760.27
+1.46%
T. Rowe Price Integrated US LCV Eq
SBFIX22.270.27
+1.23%
Federated Hermes Global Allocation IS

CELC and

Correlation & Price change

A.I.dvisor indicates that over the last year, CELC has been closely correlated with IMA. These tickers have moved in lockstep 86% of the time. This A.I.-generated data suggests there is a high statistical probability that if CELC jumps, then IMA could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To CELC
1D Price
Change %
CELC100%
+4.05%
IMA - CELC
86%
Closely correlated
+1.07%
MRSN - CELC
62%
Loosely correlated
-4.44%
NEVPF - CELC
61%
Loosely correlated
N/A
SLXN - CELC
50%
Loosely correlated
+5.59%
ABOS - CELC
44%
Loosely correlated
+12.50%
More